Business Context and Reporting Period
Company: Fortress Biotech, Inc. (FBIO)
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2024
Business Model: Fortress operates as a biopharmaceutical holding company focused on acquiring and advancing assets. It generates revenue primarily through its partner company, Journey Medical Corporation (Journey), which commercializes dermatology products (e.g., Qbrexza, Accutane), and through equity holdings in various development-stage subsidiaries (e.g., Checkpoint, Avenue, Mustang). The company is classified as a "smaller reporting company."
Key Financial Metrics
| Metric ($ in thousands) | Q3 2024 | Q3 2023 | 9M 2024 | 9M 2023 |
|---|---|---|---|---|
| Net Revenue | $14,629 | $34,752 | $42,555 | $64,567 |
| Net Loss (Consolidated) | $(26,694) | $(10,724) | $(94,540) | $(125,170) |
| Net Loss Attributable to Fortress | $(12,867) | $(5,045) | $(39,232) | $(51,358) |
| Net Loss Per Share (Basic/Diluted) | $(0.76) | $(0.94) | $(2.43) | $(7.94) |
| Cash and Cash Equivalents | $58,853 | $72,307 | $58,853 | $72,307 |
| Total Debt (Long-term, net) | $52,473 | $60,856 | $52,473 | $60,856 |
| Accumulated Deficit | $(734,102) | $(685,591) | $(734,102) | $(685,591) |
Note: Q3 2023 revenue included a one-time $19.3 million payment from Maruho for Qbrexza licensing, which is not present in Q3 2024.
Material Changes vs. Prior Period
- Revenue Decline: Net revenue decreased 58% in Q3 2024 compared to Q3 2023, primarily due to the absence of the one-time $19 million Maruho payment received in the prior year. Recurring product revenue from Journey decreased slightly (4%) due to lower sales of legacy products and increased rebates.
- Operating Expenses: Total operating expenses decreased 24% in Q3 2024. Research and Development (R&D) expenses dropped 53% to $9.4 million, driven by significant cost reductions at Mustang Bio (workforce reduction and asset repurchase adjustments) and lower clinical costs at Journey. Selling, General, and Administrative (SG&A) expenses remained relatively flat, increasing 1% to $22.0 million.
- Debt Restructuring: In July 2024, Fortress entered a new $50 million senior secured credit agreement with Oaktree, borrowing $35 million initially. This replaced the prior $50 million Oaktree note, which was repaid in full. The company recorded a $3.6 million loss on extinguishment of debt.
- Asset Impairment: Mustang Bio recorded a $2.6 million impairment charge in the nine months ended September 30, 2024, related to leasehold improvements and right-of-use assets following operational changes.
- Dividend Suspension: In July 2024, the Board paused monthly cash dividends on the 9.375% Series A Preferred Stock to preserve liquidity. Approximately $2.0 million in dividends were accrued but undeclared as of September 30, 2024.
Guidance, Outlook, and Risks
- Liquidity: Management believes current cash and cash equivalents ($58.9 million total, with $25.6 million at the parent entity) are sufficient to fund operations for at least the next 12 months. However, the company expects to continue incurring substantial losses and will require additional financing for R&D and commercialization.
- Product Pipeline Updates:
- Emrosi (Journey): Received FDA approval in November 2024 (subsequent event) for rosacea. This triggered a $15 million milestone payment obligation to Dr. Reddy's Laboratories and a requirement to draw the remaining $5 million on the SWK credit facility.
- Cosibelimab (Checkpoint): Biologics License Application (BLA) is under FDA review with a PDUFA date of December 28, 2024.
- Triplex (Helocyte): Phase 2 trial data for HIV/CMV co-infected adults is anticipated in Q4 2024.
- Key Risks:
- Financing: Continued operating losses and the need for capital to fund R&D. The pause in preferred dividends may limit the ability to use Form S-3 shelf registration statements for future equity raises.
- Debt Covenants: The new Oaktree agreement includes financial covenants requiring minimum liquidity ($7 million) and minimum net sales for Journey ($50 million trailing 12-month).
- Generic Competition: A significant portion of Journey's revenue comes from products without patent protection (e.g., Accutane, Targadox), exposing the company to price erosion and generic competition.
- Development Risk: Most product candidates are in early stages; failure in clinical trials or regulatory approval would materially impact the business.
Investor Verification Checklist
- Verify Liquidity Runway: Confirm the $25.6 million cash balance at the parent entity is sufficient to meet the $7 million minimum liquidity covenant under the new Oaktree agreement and fund operations for 12 months.
- Monitor Preferred Dividends: Track the accumulation of undeclared Series A Preferred dividends (currently ~$2.0 million) and the Board's timeline for resuming payments, as this impacts equity financing capabilities.
- Assess Journey Revenue Sustainability: Analyze the trajectory of Journey's product revenue excluding one-time payments, specifically monitoring the impact of generic competition on Accutane and Targadox.
- Track Debt Covenants: Monitor Journey's trailing 12-month net sales to ensure compliance with the $50 million minimum net sales test required by the Oaktree credit facility.
- Review Subsequent Events: Verify the financial impact of the Emrosi FDA approval (November 2024), including the $15 million milestone payment to Dr. Reddy's and the drawdown of the SWK credit facility.